Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

An assessment of the health and economic burdens of glaucoma.

Varma R, Lee PP, Goldberg I, Kotak S.

Am J Ophthalmol. 2011 Oct;152(4):515-22. doi: 10.1016/j.ajo.2011.06.004. Review.

PMID:
21961848
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Surveillance for ocular hypertension: an evidence synthesis and economic evaluation.

Burr JM, Botello-Pinzon P, Takwoingi Y, Hernández R, Vazquez-Montes M, Elders A, Asaoka R, Banister K, van der Schoot J, Fraser C, King A, Lemij H, Sanders R, Vernon S, Tuulonen A, Kotecha A, Glasziou P, Garway-Heath D, Crabb D, Vale L, Azuara-Blanco A, Perera R, Ryan M, Deeks J, Cook J.

Health Technol Assess. 2012 Jun;16(29):1-271, iii-iv. doi: 10.3310/hta16290. Review.

PMID:
22687263
[PubMed - indexed for MEDLINE]
Free Article
3.

The economic burden of glaucoma and ocular hypertension: implications for patient management: a review.

Rouland JF, Berdeaux G, Lafuma A.

Drugs Aging. 2005;22(4):315-21. Review.

PMID:
15839720
[PubMed - indexed for MEDLINE]
4.

Economic impact of primary open-angle glaucoma in Australia.

Dirani M, Crowston JG, Taylor PS, Moore PT, Rogers S, Pezzullo ML, Keeffe JE, Taylor HR.

Clin Experiment Ophthalmol. 2011 Sep-Oct;39(7):623-32. doi: 10.1111/j.1442-9071.2011.02530.x. Epub 2011 Jun 9. Review.

PMID:
21631669
[PubMed - indexed for MEDLINE]
5.

Cost-effective evaluation of the glaucoma suspect.

Doshi A, Singh K.

Curr Opin Ophthalmol. 2007 Mar;18(2):97-103. Review.

PMID:
17301609
[PubMed - indexed for MEDLINE]
6.

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation.

Burr JM, Mowatt G, Hernández R, Siddiqui MA, Cook J, Lourenco T, Ramsay C, Vale L, Fraser C, Azuara-Blanco A, Deeks J, Cairns J, Wormald R, McPherson S, Rabindranath K, Grant A.

Health Technol Assess. 2007 Oct;11(41):iii-iv, ix-x, 1-190. Review.

PMID:
17927922
[PubMed - indexed for MEDLINE]
Free Article
7.

Health economics, economic evaluation, and glaucoma.

Kobelt G.

J Glaucoma. 2002 Dec;11(6):531-9. Review.

PMID:
12483101
[PubMed - indexed for MEDLINE]
8.

Risk assessment in the management of patients with ocular hypertension.

Weinreb RN, Friedman DS, Fechtner RD, Cioffi GA, Coleman AL, Girkin CA, Liebmann JM, Singh K, Wilson MR, Wilson R, Kannel WB.

Am J Ophthalmol. 2004 Sep;138(3):458-67. Review.

PMID:
15364230
[PubMed - indexed for MEDLINE]
9.

Glaucoma screening: current trends, economic issues, technology, and challenges.

Nduaguba C, Lee RK.

Curr Opin Ophthalmol. 2006 Apr;17(2):142-52. Review.

PMID:
16552249
[PubMed - indexed for MEDLINE]
10.

A review of the health-related quality of life and economic impact of Parkinson's disease.

Dowding CH, Shenton CL, Salek SS.

Drugs Aging. 2006;23(9):693-721. Review.

PMID:
17020395
[PubMed - indexed for MEDLINE]
11.

Economic considerations of the diagnosis and management for glaucoma in the developed world.

Tuulonen A.

Curr Opin Ophthalmol. 2011 Mar;22(2):102-9. doi: 10.1097/ICU.0b013e3283437bf0. Review.

PMID:
21192264
[PubMed - indexed for MEDLINE]
12.

Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.

Orme M, Boler A.

Pharmacoeconomics. 2006;24(8):743-50. Review.

PMID:
16898845
[PubMed - indexed for MEDLINE]
13.

Evolving global risk assessment of ocular hypertension to glaucoma.

Fechtner RD, Khouri AS.

Curr Opin Ophthalmol. 2007 Mar;18(2):104-9. Review.

PMID:
17301610
[PubMed - indexed for MEDLINE]
14.

[Value-based medicine for glaucoma].

Hirneiss C, Kampik A, Neubauer AS.

Ophthalmologe. 2010 Mar;107(3):223-7. doi: 10.1007/s00347-009-2035-9. Review. German.

PMID:
20182735
[PubMed - indexed for MEDLINE]
15.

Current cost-effective work-up of the glaucoma suspect.

Budenz DL, Palmberg PF.

Curr Opin Ophthalmol. 1996 Apr;7(2):59-64. Review.

PMID:
10163324
[PubMed - indexed for MEDLINE]
16.

Cost of illness of glaucoma: a critical and systematic review.

Fiscella RG, Lee J, Davis EJ, Walt J.

Pharmacoeconomics. 2009;27(3):189-98. doi: 10.2165/00019053-200927030-00002. Review.

PMID:
19354339
[PubMed - indexed for MEDLINE]
17.

The economic implications of glaucoma: a literature review.

Schmier JK, Halpern MT, Jones ML.

Pharmacoeconomics. 2007;25(4):287-308. Review.

PMID:
17402803
[PubMed - indexed for MEDLINE]
18.

The burden of illness of cancer: economic cost and quality of life.

Brown ML, Lipscomb J, Snyder C.

Annu Rev Public Health. 2001;22:91-113. Review.

PMID:
11274513
[PubMed - indexed for MEDLINE]
19.

Risk and risk factors for blindness from glaucoma.

Chen PP.

Curr Opin Ophthalmol. 2004 Apr;15(2):107-11. Review.

PMID:
15021221
[PubMed - indexed for MEDLINE]
20.

Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Rubenstein LM, DeLeo A, Chrischilles EA.

Pharmacoeconomics. 2001;19(7):729-52. Review.

PMID:
11548910
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk